Brainstorm Cell Therapeutics (NASDAQ:BCLI) Posts Earnings Results, Beats Expectations By $0.04 EPS

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04, reports.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ BCLI traded up $0.01 on Tuesday, reaching $0.96. The stock had a trading volume of 60,223 shares, compared to its average volume of 19,581. Brainstorm Cell Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.69. The business’s 50-day moving average price is $0.91 and its 200 day moving average price is $0.86. The stock has a market cap of $14.22 million, a P/E ratio of -0.29 and a beta of 0.35.

About Brainstorm Cell Therapeutics

(Get Free Report)

BrainStorm Cell Therapeutics is a biotechnology company focused on developing cell therapies for neurodegenerative diseases. Its lead program, NurOwn, is an investigational treatment designed to use a patient’s own bone marrow-derived mesenchymal stem cells, modified to produce neurotrophic factors that may support nerve cells. The company has primarily studied NurOwn for amyotrophic lateral sclerosis (ALS). The therapy has been evaluated in clinical trials, including a Phase 3 study; it is investigational and has not been established as an approved treatment.

Read More

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.